First, in the 4T1 breast tumor model, IL-15SA/IL-15RαSu-Fc was effective in reducing lung metastases, dependent on CD8+ T as well as NK cells, and increased the median overall survival from 38 to 50 days post–surgical resection of the primary tumor (Figure 7). This evidence concerns the gene CD8A and breast neoplasm.